Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
about
Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor proteinRegulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasivenessThe von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor geneRegulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor proteinvon Hippel-Lindau disease: a clinical and scientific reviewNucleostemin mRNA is expressed in both normal and malignant renal tissuesThe VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activityPrevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort studySequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveVHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features.Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcomeThe inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complexOxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor proteinMutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCCPANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data.A multinodular goiter as the initial presentation of a renal cell carcinoma harbouring a novel VHL mutation.The ubiquitin system, disease, and drug discovery.Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinomaDifferences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.Adrenomedullin as a therapeutic target in angiogenesis.Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.Surgical pathology of renal epithelial neoplasms: recent advances and current status.Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.Renal toxicity and carcinogenicity of trichloroethylene: key results, mechanisms, and controversies.The role of angiogenesis in prostate and other urologic cancers: a review.Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growthThe efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibilityTwo single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma.The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation.An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects.VHL, the story of a tumour suppressor gene.Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
P2860
Q24291981-AE776F65-6B31-4824-87FD-F77A13F03CEEQ24301119-B1881620-E10A-47D9-8787-7C55977B4DC1Q24304165-20BCC503-9A9E-4D77-A030-7F75DDA31969Q24321830-879F2F36-1D4C-4BC4-AFDA-8734457A79B1Q24523680-8057A348-D5B4-423D-B96B-4CBB0F13737FQ24530637-427A2889-4E00-4611-B062-4FB83C48816DQ24622030-93D60C83-E8A5-4D39-B0B9-47B96D897AB6Q24651568-4406DAF1-BF52-4446-BAEC-1B2F1DD1C337Q24676311-6BF43ED8-FD3E-4542-8D40-ECA599064B1CQ24813050-B1E2F18F-477E-4AD1-83F3-957765F6B7E4Q26744089-D5970788-DAAE-45AE-98D2-F279B8C6DD45Q27824781-15FC5660-ACFF-4523-973B-EE3A77461D53Q28360494-FA9AD373-9553-43F4-A18C-B34984746597Q28486028-79EE47C2-EB90-4AB9-93B8-2BFB6D20CB6CQ28582367-E31D508A-15F2-4CD0-A69F-8C097A12205BQ28647626-DE3AEE8B-2100-4191-89D7-0174F3AD5F57Q29937783-191F5C06-30B2-4E19-BA78-62F20EB09169Q30964474-59C8AF7E-173A-45FB-8A22-E67BE19816A0Q33261672-F13D48EA-EDD8-433F-9091-AAA340D405C9Q33384295-7B6F4C0F-66B4-40F1-979F-7AD075A220B5Q33473894-89804652-6D23-4DD8-A725-7B714095A98DQ33481999-CE1BF5C8-CABD-48B8-B7FF-DD34EC2602D8Q33682913-323EBBD1-7214-472F-ABB6-FAF2DF0BD2B9Q33693793-9E073827-D1DB-4EE4-8696-9E65FD692D11Q33837015-C0A6C120-C91A-461D-8CAA-4B0DBF9EBF0BQ33848569-3C57C524-DFD8-4D97-998A-F01F08AA7DDFQ33918504-0A90E93B-18CE-439D-AAF5-22EBC049548AQ33942236-16213AE3-4538-43DE-8AF6-2DEA14AB14D7Q33955367-1E0A412A-9DF2-491E-A81A-9F39C0409E45Q33998089-75CFEBD3-4789-4A6F-9ABC-617E07F8BC60Q34001234-CEA97830-9DD0-4DCE-B566-E8C6F01516C4Q34091273-140016B4-63A8-44CD-8776-0536F481CA39Q34144574-C8A7B839-B5FA-4908-B117-5BE34EB51205Q34208511-EE952513-0724-48F5-8854-22012FBFBA00Q34235680-5C9F0A2C-7C41-4414-8859-088BC7B625C7Q34385809-6F41F69F-B3BC-413A-91D1-C94A9D8AEB04Q34387297-16BFDA30-A70D-4919-B193-013A42401FE9Q34455226-AA3AEFAE-CDD3-4153-859E-CC3E020B802DQ34589207-539DA139-1D6E-41C1-A901-C311B460C7F7Q34854941-A058C57C-7F44-4E5B-9846-7D70F4E0F0AF
P2860
Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
description
1994 nî lūn-bûn
@nan
1994 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@ast
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@en
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@nl
type
label
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@ast
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@en
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@nl
prefLabel
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@ast
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@en
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@nl
P2093
P356
P1476
Somatic mutations of the von H ...... al clear cell renal carcinoma.
@en
P2093
Crossey PA
Ferguson-Smith MA
Hulsbeek MM
Richards FM
van den Berg A
P304
P356
10.1093/HMG/3.12.2169
P577
1994-12-01T00:00:00Z